Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intracutaneous Drug Delivery Clear all
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

NCT02745392
View directory record Official record
Conditions
Acute Migraine
Interventions
ZP-Zolmitriptan, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional

A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen

NCT00000782
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG), gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
4
States / cities
Palo Alto, California • San Jose, California • San Mateo, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00376090
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-CMDR, Placebo
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 25, 2026, 7:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Optimization of the PharmaJet Needle-Free Intradermal Delivery System

NCT01494571
View directory record Official record
Conditions
Functionality and Performance of Device
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Months to 14 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

NCT01984983
View directory record Official record
Conditions
Venezuelan Equine Encephalitis Virus Infection
Interventions
Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo
Biological · Other
Lead sponsor
Ichor Medical Systems Incorporated
Industry
Eligibility
18 Years to 49 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects

NCT01324843
View directory record Official record
Conditions
Intradermal Electroporation
Interventions
EMLA Cream, Aveeno Daily Moist, Derma Vax, Intradermal Electroporation, Visual Analogue Scale, Present Pain Intensity, McGill Pain Questionnaire, Skin Assessment
Drug · Device · Procedure
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:48 PM EDT
Recruiting Phase 4 Interventional

OnabotulinumtoxinA for Trigeminal Neuralgia

NCT06216886
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
OnabotulinumtoxinA 100 UNT [Botox], Sodium Chloride 0.9% for Injection, Preservative Free
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Not applicable Interventional

Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

NCT00000955
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
14
States / cities
New Haven, Connecticut • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia

NCT00373893
View directory record Official record
Conditions
Pain, Hyperalgesia
Interventions
Lidoderm Patch
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2006 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SKIN WHEAL - Subcutaneous or Intradermal Lidocaine in Epidural for Laboring Pain.

NCT06236126
View directory record Official record
Conditions
Analgesia, Obstetrical
Interventions
1% Lidocaine Injection
Procedure
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 25, 2026, 7:48 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT

NCT05327426
View directory record Official record
Conditions
Poliomyelitis
Interventions
Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional

A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces

NCT01093833
View directory record Official record
Conditions
Diabetes
Interventions
BD Continuous glucose monitor (BD CGM), YSI Glucose Analyzer, Medtronic Guardian CGM
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

NCT01518478
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluzone® Intradermal (Sanofi Pasteur Inc.)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional

Phase I Study of Vaccination Schedule of Experimental HIV Vaccines

NCT00321061
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00, VRC-HIVADV014-00
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

NCT00614731
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KLH carrier-protein
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 25, 2026, 7:48 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

NCT00013572
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

NCT02531685
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 25, 2026, 7:48 PM EDT
Not yet recruiting Early Phase 1 Interventional

Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

NCT07697274
View directory record Official record
Conditions
Systemic Sclerosis, Sclerodactyly
Interventions
Hyaluronidase (Hylenex)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 7:48 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes

NCT01684956
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Intradermal injection, Subcutaneous injection
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients

NCT01179282
View directory record Official record
Conditions
ALLERGIC RHINITIS
Interventions
dust mite extract or placebo
Biological
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

NCT02146781
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
Biological · Other
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Not applicable Interventional Results available

Biolinq Safety and Effectiveness Trial

NCT06229743
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus
Interventions
Biolinq System
Device
Lead sponsor
Biolinq Inc.
Industry
Eligibility
22 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
6
States / cities
Escondido, California • Walnut Creek, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults

NCT02431767
View directory record Official record
Conditions
HIV Infections
Interventions
PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
4
States / cities
Decatur, Georgia • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 25, 2026, 7:48 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

NCT03282227
View directory record Official record
Conditions
Migraine
Interventions
M207 Microneedle System
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 25, 2026, 7:48 PM EDT